


REMARKS

Claims 42 and 43 have been rewritten at the suggestion of the Examiner in the Advisory Action of December 24, 2002 to place the claims in better form for allowance. The claims have not been rewritten for any reason related to patentability.

It is now submitted that this application is now in condition for allowance and the allowance is earnestly solicited. If there are any remaining issue(s) which may need further consideration, the Examiner is cordially invited to telephone the undersigned to discuss them.

Respectfully submitted,



Robert E. McCarthy (Reg. No. 46,044)

Representative Capacity

Anthony J. Zelano (Reg. No. 27,969)

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza I

2200 Clarendon Boulevard, Suite 1400

Arlington, Virginia 22201

Direct Dial: (703)812-5322

Facsimile: (703)243-6410

Filed: January 30, 2003

K:\Merck\1694d2\reply to advisory action 12-24-02.wpd

VERSION WITH MARKING TO SHOW CHANGES MADE TO THE CLAIMS

42. (Twice Amended) An isolated antibody which specifically binds to an epitope ~~from~~ ~~only one of the~~ selected from the group consisting of one of the following peptides: SEQ ID NO: 17, 20, 26, 29, 30 and ~~or~~ 31 of the p60 protein from *Listeria monocytogenes* and wherein said antibody does not cross-react with an epitope from other non-pathogenic *Listeria* species.

43. (Twice Amended) An isolated antibody which can be prepared by immunizing an experimental animal with ~~only one of the~~ with a peptide selected from the group consisting of one of the following peptides: SEQ ID NO: 17, 20, 26, 29, 30 and ~~or~~ 31, or with an immunogenic conjugate which comprises a peptide selected from the group consisting of one of the following peptides: SEQ ID NO: 17, 20, 26, 29, 30 and ~~or~~ 31, wherein said antibody specifically binds to the p60 protein from *Listeria monocytogenes*.